BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 25560470)

  • 1. Pharmacogenomics of glinides.
    Chen M; Hu C; Jia W
    Pharmacogenomics; 2015 Jan; 16(1):45-60. PubMed ID: 25560470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus.
    Malaisse WJ
    Treat Endocrinol; 2003; 2(6):401-14. PubMed ID: 15981944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.
    Pratley RE; Foley JE; Dunning BE
    Curr Pharm Des; 2001 Sep; 7(14):1375-97. PubMed ID: 11472274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
    Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial.
    Li J; Tian H; Li Q; Wang N; Wu T; Liu Y; Ni Z; Yu H; Liang J; Luo R; Li Y; Huang L
    Diabetes Obes Metab; 2007 Jul; 9(4):558-65. PubMed ID: 17587398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum.
    Shigeto M; Katsura M; Matsuda M; Ohkuma S; Kaku K
    J Pharmacol Exp Ther; 2007 Jul; 322(1):1-7. PubMed ID: 17409272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of nateglinide in the management of patients with type 2 diabetes.
    Tentolouris N; Voulgari C; Katsilambros N
    Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meglitinide analogues in the treatment of type 2 diabetes mellitus.
    Landgraf R
    Drugs Aging; 2000 Nov; 17(5):411-25. PubMed ID: 11190420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulinotropic meglitinide analogues.
    Dornhorst A
    Lancet; 2001 Nov; 358(9294):1709-16. PubMed ID: 11728565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
    Kikuchi M
    Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus.
    Füchtenbusch M; Standl E; Schatz H
    Exp Clin Endocrinol Diabetes; 2000; 108(3):151-63. PubMed ID: 10926309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
    McLeod JF
    Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Structures and mechanisms for non SU insulin secretagogues].
    Kikuchi M
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():362-70. PubMed ID: 12387019
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
    Baron MA
    Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
    [No Abstract]   [Full Text] [Related]  

  • 17. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
    Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
    Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
    Nakashima E
    Nihon Rinsho; 2015 Mar; 73(3):416-23. PubMed ID: 25812367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.